Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Eton Pharmaceuticals Acquires Exclusive U.S. Rights To PKU GOLIKE® From Relief Therapeutics, Expects To Be Accretive To Earnings In 2024

Author: Benzinga Newsdesk | March 22, 2024 02:29am

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point
Transaction is expected to be accretive to 2024 earnings
Estimated peak sales of more than $10 million annually
U.S. phenylketonuria ("PKU") medical formula market estimated to be $100 million annually

Posted In: ETON RLFTF